Clinical Case Report on the Use of Rezafungin in Pneumocystis jirovecii Pneumonia in a Critically Ill Patient
Microorganisms · 18.03.2026 · 14 (3) · 683
DOI: 10.3390/microorganisms14030683 ↗Kurz gefasst
Fallbericht in der Zeitschrift Microorganisms, online erschienen am 18.03.2026. Verfasst von Rosario Fernández-Fernández und 4 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Medicina Intensiva, Hospital Universitario Clínico San Cecilio (HUCSC), 18009 Granada, Spain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pneumocystis jirovecii pneumonia (PJP) is a life-threatening opportunistic infection predominantly affecting immunocompromised patients. Trimethoprim–sulfamethoxazole (TMP–SMX) remains the standard therapy but is often limited by severe toxicity. Rezafungin, a next-generation echinocandin with a long half-life, has shown preclinical activity against Pneumocystis spp., but its use in humans remains largely unexplored. We report the case of a 67-year-old man with inflammatory bowel disease who developed severe PJP complicated by acute respiratory failure, septic shock, and multiorgan dysfunction following corticosteroid and biologic therapy. Standard TMP–SMX therapy was contraindicated due to renal impairment and pancytopenia. The patient received rezafungin via a compassionate-use programme, with serial monitoring of serum and bronchoalveolar β-D-glucan levels. Despite a partial biomarker response, the patient ultimately progressed to refractory acute respiratory distress syndrome and multiorgan failure. This case provides preliminary human data suggesting that rezafungin may offer a potential therapeutic option for PJP when standard treatment is contraindicated or poorly tolerated. Close clinical and biomarker monitoring is essential. Further clinical and experimental studies are warranted to determine its efficacy, optimal dosing, and safety in critically ill immunocompromised patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Servicio de Medicina Intensiva, Hospital Universitario Clínico San Cecilio (HUCSC), 18009 Granada, Spain.
- Servicio de Microbiología, Hospital Universitario Clínico San Cecilio (HUCSC), 18009 Granada, Spain.
- Instituto de Investigación Biosanitaria ibs.GRANADA, 18009 Granada, Spain.
- Spanish Consortium for Research on Infectious Diseases (CIBERINFEC), Madrid, Spain.
- Faculty of Medicine, Universidad de Granada (UGR), 18016 Granada, Spain.
ORCID-Profile: Rosario Fernández-Fernández, Roberto García-Martínez, Natalia Chueca-Porcuna, Manuel Colmenero-Ruiz
Zitieren
APA
Fernández-Fernández, R., García-Martínez, R., Fernández, W. S., Chueca-Porcuna, N., & Colmenero-Ruiz, M. (2026). Clinical Case Report on the Use of Rezafungin in Pneumocystis jirovecii Pneumonia in a Critically Ill Patient. Microorganisms, 14(3), 683. https://doi.org/10.3390/microorganisms14030683
Vancouver
Fernández-Fernández R, García-Martínez R, Fernández WS, Chueca-Porcuna N, Colmenero-Ruiz M. Clinical Case Report on the Use of Rezafungin in Pneumocystis jirovecii Pneumonia in a Critically Ill Patient. Microorganisms. 2026;14(3):683. doi:10.3390/microorganisms14030683
BibTeX
@article{FernndezFernndez2026,
author = {Fernández-Fernández, Rosario and García-Martínez, Roberto and Fernández, Waldo Sánchez-Yebra and Chueca-Porcuna, Natalia and Colmenero-Ruiz, Manuel},
title = {Clinical Case Report on the Use of Rezafungin in Pneumocystis jirovecii Pneumonia in a Critically Ill Patient},
journal = {Microorganisms},
year = {2026},
volume = {14},
number = {3},
pages = {683},
doi = {10.3390/microorganisms14030683}
}
EUVIMED